Fulgent Genetics (FLGT) Payables (2015 - 2026)

Fulgent Genetics has disclosed Payables across 12 years of filings, most recently posting $16.0 million for Q2 2026.

• In Q2 2026, Payables fell 17.18% year-over-year to $16.0 million; the TTM figure through Jun 2026 stood at $16.0 million (down 17.18% YoY), while the FY2025 annual figure was $19.1 million, up 1.89% from the prior year.
• Payables came in at $16.0 million for Q2 2026 at Fulgent Genetics, down from $21.6 million in the prior quarter.
• In the past five years, Payables ranged from a high of $42.9 million in Q2 2022 to a low of $16.0 million in Q2 2026.
• Average Payables over 5 years is $22.3 million, with a median of $20.0 million recorded in 2022.
• Year-over-year, Payables jumped 180.09% in 2022 and sank 42.42% in 2023.
• Over 5 years, Payables stood at $28.7 million in 2022, then slumped by 42.42% to $16.5 million in 2023, then climbed by 13.5% to $18.8 million in 2024, then rose by 1.89% to $19.1 million in 2025, then dropped by 16.17% to $16.0 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $16.0 million in Q2 2026, $21.6 million in Q1 2026, and $19.1 million in Q4 2025.